Abnormal glucose tolerance is not only a high-risk group for diabetes, but also for cardiovascular disease. The prevention of diabetes must begin with the prevention and treatment of abnormal glucose tolerance. Epidemiological and clinical studies have shown that the incidence of abnormal glucose metabolism is significantly higher in patients with cardiovascular disease than in the general population, and therefore this group should be considered a priority target for diabetes prevention and control and glucose management. The European Heart Survey study examined the glucose metabolism status of patients admitted to the hospital for emergency or elective admission due to coronary heart disease by fasting glucose and oral glucose tolerance test, and the results showed that as many as 2/3 of patients with coronary heart disease had combined hyperglycemia. If only fasting glucose is tested, 2/3 of the hyperglycemic population will be missed. In one study, 2/3 of patients with acute myocardial infarction were discharged with missed diagnosis of prediabetes or type 2 diabetes, and long-term follow-up showed that newly diagnosed abnormal glucose metabolism was strongly associated with increased risk of cardiovascular events. In another study, a glucose tolerance test was performed in 43,509 patients at high cardiovascular risk (a subset of Chinese cases were included) and found a “2/3” (62.5%) rate of combined hyperglycemia. These studies strongly confirm that patients with cardiovascular disease are at high risk for abnormal glucose metabolism and that hyperglycemia has a significant negative impact on the prognosis of patients with coronary heart disease.